Afluria Quadrivalent Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The afluria quadrivalent market research report is one of a series of new reports that provides afluria quadrivalent market statistics, including afluria quadrivalent industry global market size, regional shares, competitors with a afluria quadrivalent market share, detailed afluria quadrivalent market segments, market trends, and opportunities, and any further data you may need to thrive in the afluria quadrivalent industry. This afluria quadrivalent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to promoting vaccination by government campaigns and healthcare providers, growing advancements in vaccine technology, increased investments by manufacturers to upgrade traditional vaccination production, increasing preference for quadrivalent vaccines among medical professionals, implementation of various programs and strategies to increase the uptake of vaccines. Major trends in the forecast period include developing innovative solutions, advanced technology providing better protection against virus mutations, innovative vaccine technologies, such as adjuvanted or quadrivalent vaccines, innovative vaccine technologies, such as adjuvanted or quadrivalent vaccines, and ongoing research and development efforts in vaccine technology.

The growing prevalence of influenza is expected to drive the growth of the afluria quadrivalent market in the coming years. Influenza, a highly contagious respiratory illness caused by influenza viruses, can lead to a range of symptoms from mild to severe, including fever, cough, and body aches. The increasing prevalence of the disease is influenced by factors such as the annual mutation of the virus, seasonal environmental changes, and low vaccination coverage in certain populations. Afluria Quadrivalent is a critical tool in addressing the rising prevalence of influenza, offering protection against four circulating flu strains. This helps reduce the risk of infection and mitigates the impact of seasonal outbreaks. For example, the UK Health Security Agency reported in November 2024 that influenza positivity rates in week 46 increased, with a weekly average positivity rate of 3.9%, up from 3.3% the previous week. The highest positivity rates were observed in individuals aged 5 to 14, with a weekly average of 11.6%, a rise from 8.8% in week 45. This trend indicates that the increasing prevalence of influenza is contributing to the growth of the afluria quadrivalent market.

The rising birth rates are expected to propel the growth of the afluria quadrivalent market. Increased birth rates can be attributed to factors such as improved healthcare, government incentives, and shifting societal attitudes. A growing number of births leads to a larger pediatric population that requires vaccination. As birth rates increase, healthcare systems are tasked with immunizing more children to prevent influenza, leading to heightened demand for vaccines like Afluria Quadrivalent. For instance, the Australian Bureau of Statistics reported in October 2024 that 24,737 Aboriginal and Torres Strait Islander births were registered in 2023, marking an increase of 349 births from 2022. This rise in birth rates is contributing to the growing demand for influenza vaccines like afluria quadrivalent.

In July 2022, Seqirus, a UK-based influenza vaccine manufacturer, formed partnerships with the Biomedical Advanced Research and Development Authority (BARDA) and the University of Liverpool Pandemic Institute. These collaborations were designed to strengthen vaccine distribution and improve public health outcomes. BARDA, a US government agency, focuses on the development of medical countermeasures for public health emergencies, while the University of Liverpool Pandemic Institute, based in the UK, works to enhance global pandemic responses through research, preparedness, and policy development.

Key player operating in the afluria quadrivalent market is Seqirus Inc.

North America was the largest region in the afluria quadrivalent market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the afluria quadrivalent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Afluria Quadrivalent is a vaccine designed to prevent infection from four different strains of the influenza virus: two strains of influenza A (H1N1 and H3N2) and two strains of influenza B. It provides protection against the flu during the annual flu season and is administered via injection. Afluria Quadrivalent is approved for use in individuals aged 6 months and older.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary clinical indications for afluria quadrivalent include seasonal influenza prevention, immunization of high-risk populations, pediatric influenza prevention, and healthcare worker vaccination. Seasonal Influenza Prophylaxis refers to the use of vaccines, such as Afluria Quadrivalent, to reduce the risk of contracting seasonal influenza caused by circulating strains. The vaccine is administered through injection or nasal spray. The target age groups include adults, geriatric patients, and pediatric patients. Distribution channels include hospitals, retail pharmacies, government suppliers, and others. The end users encompass hospitals, public and private clinics, and other healthcare facilities.

The afluria quadrivalent consists of sales of pre-filled syringes, vaccine vials, adjuvanted and unadjuvanted versions, flu vaccine kits, related packaging, and storage equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.